Ultragenyx Pharmaceutical Inc. ( RARE) - Stock Earnings
RARE Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q3 | -180.4 million USD | 159.9 million USD |
| 2025Q4 | -129.0 million USD | 207.0 million USD |
| 2026Q1 | -185.0 million USD | 136.0 million USD |
| 2026Q2 Est. | — | — |
| 2026Q3 Est. | — | — |
| 2026Q4 Est. | — | — |
RARE Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -606.6 million USD | 434.2 million USD |
| 2024 | -569.2 million USD | 560.2 million USD |
| 2025 | -575.0 million USD | 673.0 million USD |
| 2026 Est. | — | — |
RARE
Price: $25.38
52 week price:
Payout Ratio Range:
Earnings Per Share: -6.10 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 449700
Ebitda: -96.8 millionMarket Capitalization: 2.3 billion